Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEDROXYPROGESTERONE ACETATE

All products: general benefit

Other products in the same Health Canada class (G03D, G03DA) — coverage varies; not interchangeable

  • Progesterone (Prometrium): not a benefit
  • Dienogest (Visanne): limited Use 432

Provera · DIN 00708917 · 2.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued 2025-11-14 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00708917 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 2.5MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 2.5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037 · Verify on the e-Formulary ↗ (DIN 00708917)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00708917). DIN 00708917: Provera Raw flags: dinStatus=E, sec3=Y Item: 683200069; group id 801; item number 1959; lccId None; manufacturer id PFI Source form: Tab; strength: 2.5mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.2567; ministry $0.1301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00708917 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037
Interchangeable products
AA-Medroxy · DIN 02244726 · $0.1301
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for: • Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and significantly reduce the risk of hyperplasia and carcinoma; • Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the absence of organic pathology; • Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial carcinoma; • Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women. For indications not including breast cancer, AA-MEDROXY should be prescribed only to women with intact uteri. 1.1. Pediatrics Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): see 7 Warnings and precautions, 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00085517.PDF PM date: 2026-07-24 Source product: AA-MEDROXY; DIN 02244726; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.